The investigation, published in BMC Health Services Research, examined engagement from individual and interpersonal perspectives. Researchers assessed patient engagement with the Patient Engagement in Health Care Questionnaire and used its dimensions as indicators in the latent profile analysis, which identified the three groups according to their patterns of questionnaire responses. The study population was limited to patients undergoing catheter ablation for atrial fibrillation at the participating Shanghai hospitals, and its cross-sectional design captured relationships at a single point rather than changes over time.

The researchers assessed health literacy with a validated Chinese version of the All Aspects of Health Literacy Scale. They evaluated trust in physicians with the Wake Forest Physician Trust Scale, perceived physician facilitation with the Facilitation of Patient Involvement Scale and perceived social support with the Perceived Social Support Scale. Univariate analyses and multinomial logistic regression were then used to examine whether these individual and interpersonal factors were associated with membership in the three engagement profiles.

Relative to patients in the low-engagement profile, those with higher health literacy, trust in physicians and perceived physician facilitation were more likely to be classified into the medium- or high-engagement profile. Perceived social support was not significantly associated with profile membership in the analysis. These findings describe statistical associations, not causal effects: the study did not determine that changes in health literacy, physician trust or clinician facilitation would cause a patient to enter a more engaged group.

The results show that patient engagement among this group of ablation patients was heterogeneous rather than represented by a single uniform level. The largest category was the medium-engagement profile, accounting for nearly half of the sample, while the low-engagement profile represented 12.3% and the high-engagement profile 39.0%. The authors concluded that health care professionals could develop targeted interventions based on the characteristics of the different profiles, but the investigation did not test such interventions or measure their effects. Because the data came from three tertiary hospitals in one city and the study was observational and cross-sectional, the findings do not establish whether the profiles predict ablation outcomes or whether they apply to patients treated in other settings.

Subject of Research: Patient-engagement profiles and associated factors among atrial fibrillation ablation patients

Article Title: Profiles of patient engagement in health care and associated factors among patients undergoing catheter ablation for atrial fibrillation: a latent profile analysis

Article References: Xiao, G., Wu, Y., Li, S., Wang, Q., & Wu, Q. (2026). Profiles of patient engagement in health care and associated factors among patients undergoing catheter ablation for atrial fibrillation: a latent profile analysis. BMC Health Services Research. https://doi.org/10.1186/s12913-026-15130-9

Image Credits: AI Generated

DOI: 10.1186/s12913-026-15130-9

Keywords: atrial fibrillation, catheter ablation, patient engagement, latent profile analysis, health literacy, physician trust, clinical facilitation, cross-sectional study, Shanghai, health services research, Profiles, patient

Statistical tests also identified an interaction between beta-blocker use and the radiomics score, indicating that the score’s relationship with recurrence depended on preoperative medication status. Researchers screened 707 patients with atrial fibrillation and selected 555 who met the study’s eligibility criteria. They stratified the eligible cohort by long-term preoperative beta-blocker therapy and analyzed baseline clinical and echocardiographic characteristics.

Because the groups differed in measured baseline characteristics, the investigators applied inverse probability of treatment weighting before evaluating the radiomics score and its interaction with beta-blocker use. This adjustment was intended to address observed clinical imbalances between the groups, allowing the analysis to compare the score’s predictive relationship within the two treatment strata. The principal prediction model was developed in the 295 patients who had not received beta-blockers before the procedure, 50 of whom experienced atrial fibrillation recurrence.

Within this group, patients with recurrence had lower lymphocyte counts, higher body mass index and a lower prevalence of diabetes than patients without recurrence. These three clinical features were integrated with a radiomics score, or Rad-score, calculated from 11 selected left atrial appendage features. The resulting nomogram combined imaging and clinical information to estimate the probability of post-ablation recurrence.

After inverse-probability-weighting adjustment, the Rad-score was strongly associated with recurrence among patients without preoperative beta-blocker therapy, with a hazard ratio of 2.73 and P < 0.001. The corresponding association was not statistically significant among beta-blocker users: the hazard ratio was 0.91 and the P value was 0.338. The formal interaction test between Rad-score and beta-blocker use was significant at P < 0.001.

Kaplan–Meier analysis showed a related pattern: the radiomics score significantly stratified 12-month recurrence-free survival in the weighted cohort without beta-blocker therapy, with a log-rank P value below 0.001, but not in the beta-blocker group. These findings do not show that beta-blocker therapy prevents atrial fibrillation recurrence, nor do they establish that the medication removes biologically meaningful information from left atrial appendage imaging. Instead, the reported interaction shows that the radiomics score had different predictive performance and different statistical associations with observed outcomes in patients with and without long-term preoperative beta-blocker use.

The model developed without beta-blocker users therefore did not transfer effectively to the treated group, whose discrimination was close to chance at an AUC of 0.501. The results support accounting for preoperative medication history when developing or evaluating imaging-based post-ablation risk models. The study has important limitations.

The model requires multicenter external validation before its applicability can be established in independent populations, according to the researchers. Within these constraints, the clearest finding is that long-term preoperative beta-blocker use was linked to a marked difference in the ability of left atrial appendage radiomics to predict atrial fibrillation recurrence after ablation.

Subject of Research: Interaction between preoperative beta-blocker therapy and left atrial appendage radiomics for predicting post-ablation atrial fibrillation recurrence

Article Title: Interaction between long-term preoperative beta-blocker therapy and left atrial appendage radiomics in predicting post-ablation atrial fibrillation recurrence

Article References: Yang, Y., Zhong, W., Zhang, L., Zhang, X., Fang, Y., Wang, H., Jiang, X., Yu, Y., & Huang, D. (2026). Interaction between long-term preoperative beta-blocker therapy and left atrial appendage radiomics in predicting post-ablation atrial fibrillation recurrence. BMC Medical Imaging. https://doi.org/10.1186/s12880-026-02838-7

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02838-7

Keywords: atrial fibrillation, catheter ablation, beta-blockers, left atrial appendage, radiomics, recurrence prediction, clinical risk stratification, medical imaging, retrospective study, Interaction, between, long-term

Pulsed field ablation works on the principle of irreversible electroporation: extremely short, high-voltage electric pulses punch nanoscale pores into cell membranes, killing cardiomyocytes while largely sparing neighboring structures. Because different tissue types have different thresholds for irreversible injury, PFA is inherently tissue-selective. That selectivity is what has made it so attractive compared with thermal techniques such as radiofrequency and cryoablation, which can inadvertently damage the esophagus, the phrenic nerve, or the coronary arteries that lie close to the pulmonary veins—the trigger sites for most paroxysmal atrial fibrillation.

Early PFA platforms relied on monophasic pulses, which are simple to generate and highly efficient at electroporating cells, but they came with a well-documented set of problems. Monophasic stimulation provoked violent skeletal muscle contractions, required deep anesthesia, and drove unwanted electrochemical reactions at the electrodes, including polarization and gas formation. Biphasic waveforms—pairs of pulses with opposite polarity—were introduced to balance the delivered electrical charge, dramatically reducing muscle stimulation and electrochemical byproducts. Today, essentially every major commercial platform, from FARAPULSE to VARIPULSE to PulseSelect, uses some form of biphasic delivery.

But symmetric biphasic designs carry their own subtle biophysical trade-offs. When the second, opposite-polarity phase immediately follows the first, it can partially cancel the transmembrane potential that the first phase built up—a phenomenon known as the charge-cancellation effect. Compensating for that inefficiency requires higher electric field strengths, and pushing more energy through dense, high-frequency pulse bursts can generate unintended Joule heating, microbubble formation, and acute hemolysis. Those complications are not theoretical: silent cerebral lesions and hemolysis-related kidney injury have both emerged as safety concerns in the broader PFA literature.

The Chinese team, led by researchers at Tianjin Medical University and collaborating hospitals, took a different route. Their system delivers each pulse as an asymmetric biphasic waveform—a 7-microsecond positive phase followed by a 3-microsecond negative phase, separated by a 5-microsecond interval—at an amplitude of 1,000 volts. The catheter itself is a 10.5 French device with six adjustable splines, each carrying a single electrode. During each pulse, three electrodes act as anodes and three as cathodes. The catheter can be partially expanded into a basket shape to advance into a pulmonary vein, then fully deployed into a flower configuration with a maximum diameter of 32 millimeters at the vein’s ostium, maximizing tissue contact for ablation.

The trial, registered as ChiCTR2200062157, enrolled patients between January 2022 and December 2024. All had symptomatic paroxysmal atrial fibrillation that had failed or could not be tolerated on at least one class I or class III antiarrhythmic drug. Fifteen patients withdrew before the procedure, leaving 105 who underwent ablation and completed the prespecified 12-month follow-up. The cohort had a mean age of 63.7 years, was 60 percent male, and carried a mean CHA2DS2-VASc stroke-risk score of 1.54. Procedures were performed under general anesthesia or conscious sedation with uninterrupted oral anticoagulation and heparin to maintain an activated clotting time of at least 300 seconds.

The procedural results were striking. All 420 targeted pulmonary veins were acutely isolated—a 100 percent acute success rate—and no vein reconnected during the mandatory 20-minute waiting period after ablation. The mean ablation time, from the first PFA application to the last, was just under 219 seconds, and the mean total procedure time was about 102 minutes. Post-ablation voltage mapping, performed in roughly half the patients at the operator’s discretion, confirmed complete isolation at the pulmonary vein antra with no evidence of unintentional lesion formation elsewhere in the left atrium.

At 12 months, the Kaplan–Meier estimate of freedom from atrial arrhythmia recurrence—atrial fibrillation, flutter, or tachycardia lasting at least 30 seconds on protocol-specified monitoring—was 69.5 percent, with a 95 percent confidence interval of 60.1 to 77.5 percent. That figure sits comfortably within the range reported for other PFA technologies. The SINGLE SHOT CHAMPION trial reported 62.9 percent one-year freedom from recurrence, the PULSED AF Pivotal Trial reported 66.2 percent, and the VOLT-AF IDE study reported 81.1 percent. Importantly, no patient in the Chinese trial underwent repeat ablation during the 90-day blanking period, whereas several comparator studies permitted repeat procedures without counting them as endpoint failures—a difference the authors flag when urging caution about direct cross-study comparisons.

On the safety front, the results were equally notable. Not a single case of pulmonary vein stenosis, phrenic nerve injury, atrioesophageal fistula, stroke, cardiac tamponade, or acute kidney injury was recorded across the entire 12-month follow-up. The primary safety endpoint—a predefined serious adverse event—occurred in just one patient (0.95 percent), who experienced a transient coronary vasospasm on postoperative day three that resolved completely after intracoronary vasodilator administration. That patient had a pre-existing high-grade atherosclerotic coronary lesion, and while the authors acknowledge that a contributory role of the PFA procedure cannot be entirely excluded, the episode underscores a known pattern: ST-segment elevation during or after PFA should prompt urgent coronary angiography and nitroglycerin, and prophylactic nitrates may be worth considering when ablating near coronary arteries.

Two secondary safety signals deserve attention. Silent cerebral lesions, detected on brain MRI 12 to 48 hours after ablation, appeared in two patients (1.9 percent)—a rate lower than the 6.7 to 12.9 percent reported in some other PFA studies. The lesions disappeared completely on follow-up imaging at three and six months. The authors attribute the low rate partly to their waveform choice, noting that bench tests showed biphasic waveforms generate fewer microbubbles than monophasic ones, and that asymmetric biphasic pulses achieve better ablation depth than symmetric ones. Electrode geometry was also deliberately designed to avoid sharp edges and current-concentration hotspots that promote arcing and bubble formation. Meanwhile, laboratory hemolysis was common—87.6 percent of patients met the prespecified definition, with significant drops in haptoglobin and rises in lactate dehydrogenase and free plasma hemoglobin—but creatinine levels were unchanged and no patient developed acute kidney injury. The authors credit their asymmetric waveform, the basket-type catheter with single-sided electrodes that keeps current focused on tissue rather than blood, and a standardized peri-procedural saline hydration protocol. The study has limitations worth noting: it was single-arm with no comparator, lacked continuous implanted rhythm monitoring, enrolled a relatively modest sample, and excluded patients with significant renal impairment, so the hemolysis findings may not generalize to that population. Still, as a real-world, multicenter demonstration that a re-engineered pulse waveform and catheter geometry can deliver complete pulmonary vein isolation with an exceptionally clean safety record, the trial adds meaningful weight to the argument that the next generation of PFA will be defined as much by waveform physics as by catheter design.

Subject of Research: Clinical evaluation of an asymmetric biphasic pulsed field ablation system for paroxysmal atrial fibrillation

Article Title: Asymmetric biphasic pulsed field ablation of paroxysmal atrial fibrillation: clinical assessment

Article References: Xu, X., Li, Y., Lu, F., Li, H., & Cai, H. (2026). Asymmetric biphasic pulsed field ablation of paroxysmal atrial fibrillation: clinical assessment. Frontiers in Cardiovascular Medicine, 13, Article 1945178. https://doi.org/10.3389/fcvm.2026.1945178

Image Credits: AI Generated

DOI: 10.3389/fcvm.2026.1945178

Keywords: pulsed field ablation, atrial fibrillation, pulmonary vein isolation, irreversible electroporation, biphasic waveform, silent cerebral lesions, hemolysis, coronary vasospasm, cardiac electrophysiology, catheter ablation, clinical trial, Tianjin Medical University

The coronary angiographic findings deserve particular emphasis. Coronary air embolism is a recognized but uncommon event, usually described in the context of cardiac surgery, percutaneous procedures, or right-to-left shunts, and it is exceptionally rare as the presenting manifestation of an atrioesophageal fistula. In this patient, the operator could see gas as a mobile, lucid filling defect in the mid right coronary artery on the very first contrast injection, with TIMI grade 0 flow distally. Aspiration with the catheter removed a large volume of gas without any thrombus, and antegrade flow immediately returned to TIMI grade 3. That sequence is diagnostically powerful: the absence of thrombus or atherosclerotic occlusion, the instantaneous restoration of flow after aspiration, and the simultaneous presence of intravascular gas elsewhere on imaging together rule in gas embolism as the mechanism of the inferior ST elevation rather than plaque rupture or coronary spasm. It also demonstrates a practical point for interventional cardiologists, namely that aspiration can be both diagnostic and therapeutic in suspected coronary air embolism, restoring perfusion even when the underlying source of the gas cannot be corrected at the same sitting.

The electrocardiographic distribution of injury adds another layer of plausibility. The right coronary artery supplies the inferior wall in most individuals, and the ST-segment elevation in leads II, III, and aVF matched the angiographic location of the gas. Transient ST elevation from air embolism has been reported before, but it is easily mistaken for acute plaque rupture, which can lead to inappropriate delays while anticoagulation, loading with antiplatelet agents, or plans for percutaneous intervention are considered. In a patient weeks after left atrial ablation, the combination of abrupt neurologic depression, fever, and ST elevation should immediately raise suspicion for systemic air embolism from a fistula, and emergency angiography in this setting can be justified both to treat the ischemic event and to document its mechanism.

The microbiology in this case reinforces the pathophysiologic model. Blood cultures grew Streptococcus constellatus together with small quantities of other streptococci. S. constellatus belongs to the anginosus group, organisms that colonize the oropharynx, gastrointestinal tract, and genitourinary tract and are well known for abscess formation and bacteremia arising from mucosal disruptions. Isolation of such organisms from the bloodstream shortly after the abrupt clinical deterioration is difficult to explain by any mechanism other than translocation of esophageal or oral contents into the left atrium. It also helps distinguish fistula-related sepsis from the low-grade fevers that can accompany uncomplicated pericarditis or esophageal ulceration after ablation. In practice, when blood cultures from a post-ablation patient with neurologic findings grow oral or enteric streptococci, the pretest probability of an atrioesophageal fistula rises substantially, and empiric broad-spectrum antibiotic coverage covering streptococci and anaerobes should be started without waiting for definitive imaging.

The imaging strategy in this case reflects the delicate balance between diagnostic certainty and patient safety. Non-contrast computed tomography of the head and chest was performed rapidly and showed gas in the cortical sulci, along the superior sagittal sinus, in all cardiac chambers, and in the aorta, coronary arteries, pulmonary arteries, and cervical vessels. Retrospective review identified a suspected tract between the posterior left atrial wall and the adjacent esophagus. Contrast-enhanced computed tomography, which would have provided the strongest direct evidence of a fistulous connection, was not performed because the patient was hemodynamically unstable. Upper gastrointestinal endoscopy and transesophageal echocardiography were deliberately avoided, consistent with the widely held view that endoscopic insufflation can propel additional gas and esophageal contents through the fistula into the arterial circulation and worsen neurologic injury. This is a recurring dilemma in the literature: the tests that would confirm the diagnosis are the same tests that may accelerate the disease. Most experts therefore recommend that when the clinical syndrome and non-invasive imaging are sufficiently suggestive, treatment should proceed on the presumptive diagnosis, with surgical consultation obtained immediately, rather than waiting for endoscopic or contrast confirmation that may never be safely obtainable.

Timing is another consistent theme. The fistula in this patient declared itself approximately one month after ablation, which falls squarely within the typical window. Published series describe symptom onset most often in the second to fourth week after the procedure, with a mean interval of roughly two to three weeks, and the esophageal ulceration that precedes fistulization has been documented endoscopically within days of radiofrequency delivery. The delay occurs because the thermal injury must deepen through the esophageal mucosa and muscularis before the wall is breached. This latent period has two practical consequences. First, patients and clinicians should not consider the danger period over at hospital discharge; symptom education must extend for at least a month, and any new fever, chest pain, dysphagia, odynophagia, hematemesis, seizure, stroke, or altered mental status in that window warrants urgent evaluation. Second, the delayed onset means the causal connection to the ablation is easy to miss, particularly when the patient presents to a facility that did not perform the procedure, as happened here. Procedural details were unavailable to the treating team, which likely contributed to diagnostic uncertainty during the first hours.

Prevention remains the most effective intervention, because survival once the fistula is established is poor even with prompt surgery. Radiofrequency energy is not tissue selective, and the esophagus lies immediately posterior to the left atrium in many patients, sometimes separated by only a few millimeters of tissue. The distance between the esophagus and the posterior left atrial wall has been identified as an important risk factor, and esophageal ulcers have been found in a small but meaningful fraction of patients screened endoscopically after ablation. Strategies to reduce risk include limiting posterior wall radiofrequency power and duration, monitoring esophageal temperature during ablation, and using active esophageal cooling devices, which have been proposed to lower the risk of fistula formation. Mechanical esophageal displacement, luminal esophageal temperature probes, and the choice of energy source, including cryoablation or pulsed field ablation with its theoretical tissue selectivity, are areas of ongoing study. Post-procedural acid suppression and treatment of gastroesophageal reflux may also matter, because reflux is thought to promote the progression from superficial ulcer to deep fistula.

The hemodynamic and laboratory evolution in this patient tracks the expanding injury. Early point-of-care testing showed only modest myoglobin elevation with near-normal troponin, but by ten hours the high-sensitivity troponin had risen to more than 6,000 ng/L and ultimately exceeded 25,000 ng/L, reflecting extensive myocardial necrosis from coronary embolism and prolonged shock. Interleukin-6 above 5,000 pg/mL signaled a profound systemic inflammatory response driven by bacteremia and tissue injury. Recurrent bradycardia and hypotension preceded cardiac arrest, and death occurred approximately twenty-seven hours after admission despite antibiotics, anticoagulation, antiplatelet therapy, statin, and vasopressor support. Surgical repair was considered but deferred because refractory shock made perioperative survival unlikely. This outcome mirrors the published experience, in which mortality for atrioesophageal fistula remains high even in surgically treated patients, and delays of more than twenty-four hours between symptom onset and repair are associated with markedly worse survival. The lesson is that the window for salvage is measured in hours, and the decision to operate must often be made on clinical suspicion alone.

Finally, the authors’ caution about diagnostic certainty is worth underscoring. The case demonstrates direct angiographic visualization of intracoronary gas and successful catheter aspiration, and it shows multisite intravascular gas on non-contrast imaging together with bacteremia from organisms characteristic of the oropharyngeal and gastrointestinal flora. These findings together make the diagnosis of an atrioesophageal fistula complicated by systemic air embolism highly probable, but the fistulous tract itself was only a retrospective suspicion on non-contrast imaging, never confirmed by contrast-enhanced cross-sectional imaging, endoscopy, or surgery. Reporting the case with that limitation intact is scientifically honest and clinically useful, because it models the epistemic situation clinicians actually face: the evidence is often strong but incomplete, the confirmatory tests are hazardous, and the cost of waiting is death. For clinicians, the practical synthesis is straightforward. In any patient within several weeks of atrial fibrillation ablation who presents with fever, new neurologic deficits, altered consciousness, seizures, or acute ST-segment elevation, atrioesophageal fistula with systemic air embolism belongs at the top of the differential diagnosis. Immediate computed tomography of the head and chest, blood cultures, empiric antibiotics, avoidance of endoscopy and esophageal instrumentation, urgent cardiothoracic surgical consultation, and consideration of hyperbaric oxygen therapy where available constitute the appropriate initial response, and coronary angiography with aspiration can play a defined role when myocardial ischemia is the dominant manifestation.

Subject of Research: Cardiovascular Medicine

Article Title: Suspected atrioesophageal fistula complicated by coronary air embolism after catheter ablation for atrial fibrillation: direct angiographic visualization and catheter aspiration in a case report

Article References: Yang, C., Zeng, X., Wang, S., Wang, C., Lan, J., Wen, Y., & Zheng, Z. (2026). Suspected atrioesophageal fistula complicated by coronary air embolism after catheter ablation for atrial fibrillation: direct angiographic visualization and catheter aspiration in a case report. Frontiers in Cardiovascular Medicine, 13, Article 1985470. https://doi.org/10.3389/fcvm.2026.1985470

Image Credits: AI Generated

DOI: 10.3389/fcvm.2026.1985470

Keywords: atrial fibrillation, catheter ablation, atrioesophageal fistula, coronary air embolism, case report, radiofrequency ablation, Streptococcus constellatus, coronary angiography, left atrium, esophageal injury, cardiac arrest, Frontiers in Cardiovascular Medicine

The research, published in BMC Pediatrics, comes from a team at Shanghai Children’s Medical Center led by Xinyi Xu and colleagues, including corresponding author Tingliang Liu. The investigators combed through fifteen years of clinical records, spanning 2009 to 2024, at their tertiary children’s hospital in China. From that archive they identified 101 children diagnosed with tachycardia-induced cardiomyopathy, 58 of them boys. The median age at diagnosis was strikingly young: just 1.4 years, with the middle half of patients falling between roughly four months and seven years old. That age profile alone tells an important story, because it means the condition frequently strikes infants and toddlers, patients too young to describe palpitations or chest discomfort and whose symptoms are easily mistaken for ordinary childhood illness.

The central finding concerns the arrhythmias that set the disease in motion. Focal atrial tachycardia, an abnormal rhythm originating from a discrete spot in the heart’s upper chambers, accounted for 55.4 percent of cases, making it by far the most common culprit. Other rhythm disturbances in the pediatric TIC spectrum include atrial flutter, atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia, chaotic atrial tachycardia, junctional ectopic tachycardia, and ventricular tachycardia. Each of these rhythms forces the ventricles, the heart’s main pumping chambers, to beat far faster than they were designed to. When that pace persists, the heart muscle exhausts itself in a way that cardiologists compare to a sprinter forced to run a marathon: the chambers dilate, the pumping fraction measured by echocardiography falls, and the child can slide into heart failure.

What makes TIC clinically fascinating, and diagnostically treacherous, is that the muscle damage is potentially reversible. Unlike many cardiomyopathies, which reflect intrinsic disease of the heart muscle itself, TIC is a secondary phenomenon: remove or control the arrhythmia, and the pump often recovers. The Shanghai team’s data quantify just how often that recovery happens. At a median follow-up of 34 months, ranging from 14 to 67 months, the tachyarrhythmia driving the disease had resolved spontaneously in 46 of the 101 patients, or 45.5 percent. In other words, in nearly half the cohort, the abnormal rhythm simply stopped on its own over time, and with it the stimulus that had been wearing the heart down.

The study goes beyond describing outcomes by identifying which children recover fastest. Using statistical modeling, the researchers pinpointed three independent predictors of recovery of the left ventricular ejection fraction, the standard measure of pumping strength. The first was age at TIC onset: each additional year of age at diagnosis was associated with a hazard ratio of 0.912 for ejection fraction recovery, with a 95 percent confidence interval of 0.863 to 0.964 and a p-value of 0.001. In practical terms, older children recovered more slowly than infants. The second predictor was the nature of the rhythm itself: incessant tachycardia, meaning an arrhythmia present nearly continuously rather than in intermittent bursts, carried a hazard ratio of 0.480, indicating markedly slower recovery of pumping function. The third was the baseline degree of left ventricular dilation, measured as the end-diastolic dimension Z-score, a statistical correction that accounts for a child’s body size. For every one standard deviation increase in that Z-score, the hazard ratio for recovery was 0.828, meaning a more stretched-out ventricle at diagnosis predicted a slower climb back to normal function.

These predictors give clinicians a practical risk stratification tool. A toddler whose heart races around the clock and whose left ventricle is already significantly dilated at presentation is the patient who will need the most aggressive rhythm control and the closest monitoring. Conversely, an infant with a milder, intermittent arrhythmia and a ventricle that is only mildly enlarged has a good prognosis even before treatment begins. The findings also reinforce a principle that pediatric cardiologists have long suspected: the duration and burden of the tachycardia, not merely its type, determine how much the heart suffers and how long it takes to heal.

Infants, however, occupy a paradoxical position in the study’s results. On one hand, children aged one year or younger had dramatically better odds of spontaneous resolution of their arrhythmia, with an odds ratio of 8.309 compared with older children. The immature heart’s conduction system, for reasons the study does not fully resolve, appears more likely to simply outgrow certain abnormal rhythms. On the other hand, when infants did require catheter ablation, the procedure that threads catheters into the heart to destroy the tissue generating the abnormal rhythm, their complication rates were sobering. Ablation-related adverse events occurred in 66.7 percent of children one year old or younger, two out of three patients in that small subgroup, compared with just 8.7 percent of children older than one year, four out of 46. The difference was statistically significant, with a p-value of 0.04.

That trade-off sits at the heart of the clinical dilemma the study illuminates. Ablation in a tiny infant is technically demanding: the heart is the size of a walnut, the arrhythmia focus may be millimeters across, and the catheters and mapping systems were largely engineered for adult anatomy. Yet waiting for spontaneous resolution is not always safe when the heart is failing. The study’s numbers suggest a reasoned approach: in infants, particularly those whose arrhythmias are intermittent and whose ventricles are not severely dilated, a strategy of medical rhythm control and watchful waiting may be justified by the high likelihood of spontaneous resolution. In older children, where spontaneous resolution is less common and ablation is far safer, earlier catheter-based intervention becomes more attractive, especially when the arrhythmia is incessant and the clock is ticking on ventricular recovery.

The broader significance of the study lies in its scale and duration. Fifteen years of single-center experience with 101 patients is a substantial dataset for a condition that most pediatric centers encounter only a handful of times per decade. Because the analysis is retrospective, it inherits the limitations of that design: treatment decisions were made by individual clinicians rather than a protocol, and the findings describe associations rather than the effects of randomized interventions. Still, the consistency of the three prognostic factors, age, arrhythmia persistence, and ventricular dilation, across the statistical models gives the results weight, and the cohort size lends the estimates a precision that smaller case series cannot match.

For families, the headline message is ultimately an encouraging one. Most children in the study recovered fully once their heart rhythm was brought under control, whether through medication, ablation, or the arrhythmia’s own spontaneous disappearance. Tachycardia-induced cardiomyopathy, frightening as it sounds when a child’s ejection fraction plummets, is in most cases a temporary state rather than a permanent sentence. The challenge, as the Shanghai data make clear, is matching the right treatment to the right child at the right time: protecting the hearts of infants whose rhythms may resolve on their own, while moving decisively in older children whose incessant arrhythmias and dilated ventricles signal a longer, harder road to recovery. With this fifteen-year map in hand, pediatric cardiologists now have firmer ground on which to make those decisions.

Subject of Research: Clinical management and prognosis of tachycardia-induced cardiomyopathy in children

Article Title: Clinical management and prognosis of tachycardia-induced cardiomyopathy in children: a retrospective cohort study with 15-year single-center experience

Article References: Xu, X., Feng, W., Wang, K., Ji, W., Guo, Y., Wu, J., Chen, Y., Zhu, D., Li, F., & Liu, T. (2026). Clinical management and prognosis of tachycardia-induced cardiomyopathy in children: a retrospective cohort study with 15-year single-center experience. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07712-7

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07712-7

Keywords: tachycardia-induced cardiomyopathy, pediatric cardiology, arrhythmia, focal atrial tachycardia, catheter ablation, left ventricular ejection fraction, heart failure in children, spontaneous resolution, infants, retrospective cohort study, echocardiography, prognosis

The research, led by Mengyuan Jing, Haoxiang Lu, and Qing Liu with colleagues at Lanzhou University Second Hospital, the Guangdong Cardiovascular Institute, and partner institutions, set out to build an explainable machine learning model that could predict functional improvement after ablation in patients with atrial fibrillation combined with heart failure. Rather than relying on a single measurement, the team fused three complementary streams of information: the geometry of the left atrium and pulmonary veins as seen on cardiac CT angiography, quantitative radiomics features extracted from the left atrial wall, and a handful of routine clinical variables. The result was a combined model, dubbed COMB, that achieved an area under the receiver operating characteristic curve of 0.866 in the training set, 0.803 in the validation set, and 0.845 in an independent testing set drawn from other hospitals.

Those numbers deserve unpacking, because the area under the curve, or AUC, is the workhorse metric for judging how well a model separates patients who will improve from those who will not. A value of 0.5 would mean the model performs no better than a coin flip, while 1.0 would indicate perfect discrimination. Scores consistently above 0.80 across three separate patient cohorts, including an external test set the model had never encountered during development, represent solid, clinically meaningful performance. Equally important is how the team arrived at that performance. Patients from the primary institution were randomly divided into training and validation sets in a seven-to-three ratio, while two other organizations contributed entirely separate testing cohorts, a design that guards against the model simply memorizing the quirks of one hospital’s scanner or patient population.

The technical heart of the study lies in what the researchers chose to measure. Cardiac CT angiography, already a routine part of pre-ablation planning because it maps the pulmonary veins before catheter insertion, provides exquisitely detailed three-dimensional images of the left atrium, the chamber where fibrillation typically originates. From these images the team extracted morphological features describing the shape of the left atrium and the pulmonary veins, capturing subtle geometric signatures such as chamber distortion and remodeling that a human reader might overlook. In parallel, they applied radiomics, a computational approach that converts medical images into hundreds of quantitative descriptors of texture, intensity, and spatial pattern, to the left atrial wall itself, the thin muscular sleeve where ablation lesions are created and where fibrotic change often determines whether the procedure succeeds.

From this high-dimensional feature space, the researchers distilled two focused models. Two shape features and three left atrial wall radiomics features survived rigorous screening and were used to construct what they called the Shape model and the Wall model, respectively. Each model produced a continuous score, the Shape_score and the Wall_score, which quantified how strongly a given patient’s cardiac anatomy resembled that of patients who went on to improve. These scores were then integrated with the clinical variables that proved most informative, namely gender, hyperlipidemia, blood urea level, and the type of atrial fibrillation, to yield the final combined model. The parsimony is striking: out of the vast number of features that could have been included, the final predictor rests on just a handful of imaging and clinical inputs, all obtainable from examinations and blood tests that are already standard practice.

What elevates the study beyond a typical prediction exercise is its commitment to explainability. Black-box algorithms have long been a stumbling block for clinical adoption, because physicians are understandably reluctant to act on a probability they cannot interrogate. The researchers addressed this by applying SHAP, or Shapley additive explanations, a technique borrowed from cooperative game theory that assigns each input feature a precise contribution to every individual prediction. In effect, SHAP reveals which factors pushed a particular patient’s predicted probability up or down, and by aggregating these contributions across the cohort, the team identified the features with the greatest impact on outcomes in both the Shape and Wall models. This transparency allows a cardiologist to see, for example, whether an unfavorable prediction stems from pronounced atrial remodeling, abnormal wall texture suggesting fibrosis, or a clinical factor such as persistent rather than paroxysmal fibrillation.

The clinical stakes of this kind of tool are considerable. Patients with atrial fibrillation and concomitant heart failure represent a particularly vulnerable group, and ablation in these individuals carries procedural risk, substantial cost, and a demanding recovery. If a model can reliably flag patients unlikely to experience functional improvement, clinicians could counsel them more honestly, weigh alternative management strategies such as optimized medical therapy, or reserve ablation for those with the greatest expected benefit. Conversely, identifying patients with a high predicted probability of improvement could support earlier referral and shared decision-making grounded in quantitative evidence rather than clinical intuition alone. Because the model’s inputs come from CT angiography and routine laboratory work, it could in principle be deployed without any additional testing beyond what pre-ablation workups already include.

The multicenter architecture of the study strengthens its claims in another important way. Models trained and tested within a single institution often flatter themselves, absorbing center-specific artifacts in scanner protocol, image reconstruction, and patient mix. By including 240 patients in the training set, 101 in the validation set, and 75 in external testing sets from two other organizations, the team demonstrated that the model’s discrimination held up across different hospitals and imaging environments. The ethics committees of all three participating institutions approved the retrospective study, and the requirement for individual informed consent was waived because of its retrospective design, with the work conducted in accordance with the Declaration of Helsinki.

The authors themselves are careful about the limits of what they have shown. The study was retrospective, meaning it looked backward at patients who had already undergone ablation rather than prospectively assigning the model to guide care in real time. The team explicitly states that further prospective evaluation is required before the model can be implemented clinically, a caveat that applies to nearly every prediction algorithm now emerging in cardiovascular medicine. Prospective validation would involve using the COMB model to generate predictions before ablation and then tracking whether those predictions match observed outcomes, ideally across diverse populations and healthcare systems. Questions about calibration, the agreement between predicted probabilities and actual event rates, and about how the model behaves in subgroups underrepresented in the data, would also need answers.

Even with those caveats, the study offers a compelling glimpse of where cardiac imaging and artificial intelligence are converging. The same CT scan obtained to map a patient’s pulmonary veins becomes, through shape analysis and radiomics, a quantitative portrait of atrial health, and machine learning converts that portrait, together with a few clinical facts, into an individualized forecast of recovery. The SHAP framework keeps the forecast auditable, showing clinicians exactly which anatomical and biological signals drove the conclusion. For the millions of patients whose fibrillation and heart failure travel together, and for the physicians deciding whether to offer them ablation, a tool that turns pre-procedural images into evidence-based expectations could reshape the conversation, replacing uncertainty with a number that both doctor and patient can understand, question, and trust.

Subject of Research: Explainable machine learning on cardiac CT angiography to predict functional improvement after atrial fibrillation ablation in patients with heart failure

Article Title: Explainable machine learning model based on cardiac CT angiography for predicting functional improvement after atrial fibrillation ablation: a multicenter study

Article References: Jing, M., Lu, H., Liu, Q., Jing, Y., Lei, F., Yang, X., Chen, G., Xi, H., Xin, W., Zhu, H., Sun, Q., Zhang, Y., Ren, J., Ren, W., Liu, Z., Wang, G., & Zhou, J. (2026). Explainable machine learning model based on cardiac CT angiography for predicting functional improvement after atrial fibrillation ablation: a multicenter study. BMC Medical Imaging. https://doi.org/10.1186/s12880-026-02822-1

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02822-1

Keywords: atrial fibrillation, heart failure, catheter ablation, cardiac CT angiography, machine learning, radiomics, left atrium, SHAP explainability, predictive modeling, multicenter study, BMC Medical Imaging, cardiac imaging

The research, led by Mathieu Kruska and Volker Liebe of the University Medical Centre Mannheim at Heidelberg University together with colleagues across several German institutions, enrolled eighty-three patients with symptomatic atrial fibrillation who were scheduled for catheter ablation at a single center between October 2020 and March 2022. The cohort had a median age of seventy-two years, and just over one-third of participants were women. Most patients, eighty-two percent, suffered from the paroxysmal form of the arrhythmia, in which episodes come and go rather than persist continuously. Their symptom burden was substantial: the median European Heart Rhythm Association symptom score was three, indicating moderate to severe symptoms, and their average score on a validated quality of life questionnaire was only sixty out of a possible one hundred, underscoring how heavily the condition weighed on daily living.

What sets this study apart is its multimodal approach. Before ablation, each patient underwent pulse wave analysis using an oscillometric device called VascAssist2.0, which measures blood pressure waveforms at the arm and uses a mathematical model of the arterial system to derive a suite of vascular parameters. These include brachial and central blood pressures, pulse wave velocity, augmentation pressure, augmentation index, left ventricular ejection time, and model-based indices of arterial stiffness and vascular resistance. In parallel, patients received transthoracic echocardiography to assess cardiac structure and function, a twelve-lead electrocardiogram, laboratory testing including the heart failure biomarker NT-proBNP, and a detailed quality of life assessment using the AFEQT questionnaire, a disease-specific instrument covering twenty items that captures how atrial fibrillation affects symptoms, daily activities, and treatment satisfaction.

The correlations that emerged were striking. Lower AFEQT scores, indicating worse quality of life, correlated strongly with higher vascular resistance, with a correlation coefficient of minus 0.64, and with increased arterial stiffness, at minus 0.62, both highly statistically significant. Elevated central systolic blood pressure, the pressure actually experienced by the heart and brain rather than the arm, also tracked with poorer quality of life at minus 0.38. On the cardiac side, the strongest association of all was found with reduced left ventricular ejection fraction below fifty percent, which correlated at minus 0.74 with AFEQT scores. Diastolic dysfunction, the inability of the heart’s main pumping chamber to relax and fill properly, correlated at minus 0.34, while a clinical diagnosis of heart failure correlated at minus 0.39 and logarithmically transformed NT-proBNP levels at minus 0.38. Patient-reported quality of life also aligned closely with physician-assessed symptom classification, with EHRA scores correlating at minus 0.91 with AFEQT scores, a reassuring sign that the two instruments are measuring the same underlying phenomenon from different angles.

To understand why stiff arteries should make an abnormal heart rhythm feel worse, the authors turn to the concept of ventricular-arterial and arterial-atrial coupling. When the large arteries lose their elastic cushioning, every heartbeat travels through the vascular tree faster, and reflected pressure waves return to the heart earlier in the cardiac cycle. This raises the central systolic pressure the left ventricle must pump against, increasing afterload and impairing diastolic relaxation. Higher pressures then back up into the left atrium, promoting structural and functional remodeling of that chamber, a process central to atrial cardiomyopathy. The resulting atrial substrate not only facilitates the persistence of atrial fibrillation but may also blunt the atrium’s reservoir function, intensifying symptoms such as fatigue and breathlessness. The same hemodynamic cascade is considered a central driver of heart failure with preserved ejection fraction, tying together several threads of cardiovascular medicine in a single mechanistic framework.

Intriguingly, one conventional measure of arterial health did not follow this pattern. Aortic pulse wave velocity, widely regarded as the reference standard for large-artery stiffness, was within age-adapted reference values in the cohort at a median of 8.6 meters per second and did not correlate significantly with quality of life scores. The authors suggest that pulse wave velocity predominantly reflects the structural properties of the aorta and vascular aging, whereas the model-derived vascular resistance, arterial stiffness index, and central systolic blood pressure may better capture dynamic functional afterload and ventricular-arterial coupling. Those fluctuating hemodynamic loads, they argue, may be more directly connected to the day-to-day symptoms of palpitations, dyspnea, and exercise intolerance than a static measure of aortic structure. Notably, the pulse wave measurements proved robust regardless of rhythm: over ninety percent of patients were in sinus rhythm at the time of testing, and no significant differences were found between measurements taken during sinus rhythm and those taken during atrial fibrillation.

The study also highlights the tangled relationship between atrial fibrillation and heart failure, two conditions that each fuel the other’s progression. Thirty percent of the cohort had heart failure, forty-two percent showed echocardiographic evidence of diastolic dysfunction, and elevated NT-proBNP levels were strongly associated with poorer quality of life. Disentangling which symptoms stem from the arrhythmia and which from the failing heart is notoriously difficult, since dyspnea and fatigue dominate both. Interestingly, heart failure with reduced ejection fraction was associated with impaired quality of life in this analysis, whereas the preserved-ejection-fraction phenotype did not reach statistical significance. That observation echoes earlier findings suggesting that the symptomatic benefits of ablation may be attenuated in patients with heart failure with preserved ejection fraction, possibly because their symptoms are driven more by the stiff, non-compliant cardiovascular system than by the arrhythmia itself.

Beyond the vascular and cardiac measurements, broader comorbidity burden left its mark. Coronary artery disease, older age, arterial hypertension, higher total and LDL cholesterol, and reduced kidney function all correlated inversely with quality of life scores, as did higher CHA2DS2-VASc and HAS-BLED risk scores. Taken together, these associations paint quality of life in atrial fibrillation as a barometer of overall cardiovascular health rather than a simple readout of arrhythmia burden. This aligns with large registry data linking cardiovascular comorbidities to worse patient-reported outcomes, and it reinforces current European Society of Cardiology guidelines that emphasize comprehensive management of risk factors alongside rhythm control strategies.

The authors are careful to frame their findings appropriately. The study was exploratory and hypothesis-generating, conducted at a single center with a modest sample size and no formal a priori power calculation. Because many univariate correlations were performed without adjustment for multiple testing, the reported associations should be interpreted descriptively, and the absence of multivariable modeling means the independent contribution of each vascular parameter cannot be isolated. The single-time-point, observational design precludes any causal inference, and recruitment during the COVID-19 pandemic added logistical strain to elective procedural volumes. Whether pulse wave analysis-derived vascular phenotyping genuinely adds predictive value beyond established clinical evaluation will require prospective validation in larger cohorts.

Even with those caveats, the implications are compelling. If stiff arteries, elevated central pressures, and weakened or stiffened heart muscle account for a substantial share of the suffering attributed to atrial fibrillation, then measuring them before ablation could help clinicians identify patients whose symptoms reflect more than the arrhythmia alone, and tailor treatment accordingly, with intensified blood pressure control, vascular risk management, and heart failure therapy running alongside rhythm control. For patients, the message is equally resonant: the health of the arteries is inseparable from the experience of the arrhythmia. As the authors conclude, reduced quality of life in symptomatic atrial fibrillation reflects a complex interplay between vascular function, myocardial performance, and the rhythm disorder itself, and understanding that interplay may ultimately determine who truly benefits from a procedure that millions pin their hopes on.

Subject of Research: Associations between vascular and cardiac functional parameters and quality of life in atrial fibrillation patients scheduled for catheter ablation

Article Title: Impact of vascular and cardiac parameters on quality of life in patients undergoing catheter ablation for atrial fibrillation

Article References: Kruska, M., Liebe, V., Fastner, C., Kranert, M., Jehle, M., Derda, A., Schumacher, G., Akin, I., Duerschmied, D., & Hohneck, A. (2026). Impact of vascular and cardiac parameters on quality of life in patients undergoing catheter ablation for atrial fibrillation. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-026-03005-2

Image Credits: AI Generated

DOI: 10.1007/s00392-026-03005-2

Keywords: atrial fibrillation, catheter ablation, quality of life, arterial stiffness, vascular resistance, pulse wave analysis, echocardiography, NT-proBNP, heart failure, central blood pressure, AFEQT, diastolic dysfunction

The trial enrolled 262 patients with symptomatic paroxysmal or persistent atrial fibrillation and randomised them in a 2:1 ratio to pulmonary vein isolation or to a sham procedure. The primary endpoint was the between-group difference in the change from baseline to six months in the AFEQT summary score, a well-established questionnaire measuring atrial fibrillation-related quality of life. At six months, the mean AFEQT score improved from 61 to 81 in the ablation group and from 59 to 75 in the sham group. Both improvements were clinically meaningful, but the difference in change between the groups was not statistically significant. Meanwhile, ablation demonstrated clear objective efficacy: atrial fibrillation was detected in 21 percent of ablated patients versus 41 percent of sham patients, an absolute difference of 20 percent, with a favourable safety profile.

What distinguishes PVI-SHAM-AF from earlier research is the rigor of its control condition. The sham intervention was not an inert experience but an active clinical pathway encompassing hospital admission, deep sedation and analgesia, venous access, a stay in the catheterization laboratory, cardioversion for patients who arrived in atrial fibrillation, and structured follow-up. The trial therefore tested catheter ablation against this comprehensive procedural and clinical-care package, not against no treatment at all. The investigators emphasise that the study did not evaluate conventional non-invasive ambulatory care. Within the six-month observation window, however, the superior rhythm control achieved by ablation simply did not translate into a statistically significant improvement in patient-reported quality of life beyond what the active sham pathway delivered.

Compared with the two previous sham-controlled ablation trials, SHAM-PVI and PFA-SHAM, PVI-SHAM-AF was substantially larger, exceeding the combined sample size of both predecessors. Baseline quality of life was impaired to a similar degree as in the major open-label trials CABANA and EARLY-AF. Intriguingly, while the improvement within the ablation arms was broadly consistent across all these studies, the improvement observed in the sham arm of PVI-SHAM-AF was markedly lower than in SHAM-PVI and PFA-SHAM. The editorial authors suggest this discrepancy indicates that patient management in PVI-SHAM-AF may have been more comprehensive than in the other two sham trials, intensifying the care received by the control group and thereby narrowing the apparent treatment effect on symptoms.

The findings echo a broader pattern in cardiovascular medicine. Previous reports have documented clinically relevant placebo effects in randomised trials of invasive procedures across settings as varied as resistant hypertension, percutaneous coronary intervention and vertebroplasty for osteoporotic vertebral fractures. A systematic review and meta-analysis found that only about a third of placebo-controlled trials of cardiovascular interventions demonstrated significant superiority of the invasive procedure over placebo. Against this backdrop, PVI-SHAM-AF is less an outlier than a striking confirmation that subjective, patient-reported endpoints are acutely susceptible to contextual healing, expectation and the attention that accompanies any hospital-based intervention.

Why did both groups improve so substantially? The editorial points to a likely combination of placebo and Hawthorne effects, regression to the mean, and optimised concomitant care driven by protocol-adherent assessments and intensive follow-up. Symptoms in atrial fibrillation, the authors argue, may not be determined solely by arrhythmia physiology but also by symptom perception, atrial or ventricular ectopy, anxiety and depression. Quantifying the individual contributions of these mechanisms is difficult, and PVI-SHAM-AF was not designed to isolate them. Disentangling how much of the improvement stems from the procedure itself, from heightened clinical attention, or from psychological factors remains a critical objective for future research and could reshape how symptom-directed therapies are evaluated.

Do the results mean ablation fails to relieve symptoms, or that it should be withheld from patients with preserved left ventricular function? The editorial authors firmly reject both conclusions. The trial demonstrates that ablation reduces atrial fibrillation recurrence and burden safely, and it does not challenge indications in settings where reducing arrhythmia burden may improve clinically relevant outcomes, such as tachycardia-induced or atrial fibrillation-aggravated cardiomyopathy and heart failure with reduced ejection fraction, populations that were not the focus of this study. The results are confined to patient-reported outcomes rather than morbidity or mortality, reflecting a familiar divergence in cardiology where effects on hard endpoints and on how patients feel can part ways, as seen with beta-blockers, inotropes and implantable cardioverter-defibrillators in heart failure.

Questions about patient selection and follow-up duration also deserve scrutiny. Data on the 937 patients who declined randomisation were insufficient for comparison, and willingness to accept an invasive sham procedure may have selected individuals with particular symptom burdens, expectations or treatment preferences; patients with severe symptoms might have declined to guarantee receiving ablation. Yet the mean baseline AFEQT score of 60 mirrored those in CABANA, EARLY-AF and STOP AF First, beta-blocker use remained high and balanced between groups, and no treatment effect heterogeneity by baseline score was observed. The six-month primary endpoint was chosen deliberately to minimise the impact of repeat procedures, but the authors concede it may have been too short to capture the full treatment effect, and it does not exclude longer-term benefits in rhythm control, medication use, healthcare utilisation or clinical outcomes. Twelve-month follow-up is ongoing.

For clinical practice, the implications centre on shared decision-making. PVI-SHAM-AF shows that the objective rhythm-control benefits of catheter ablation should be clearly distinguished from its effects on patient-reported quality of life at six months, information that is essential for counselling patients whose primary goal is symptom relief. The results also underscore the therapeutic power of comprehensive, attentive clinical care. Crucially, the authors stress that invasive sham procedures are research tools for delineating true treatment effects and must never be translated into clinical practice. Instead, the challenge is to identify which components of the sham-associated care pathway improved symptoms and how those elements can be incorporated into routine, non-invasive care.

Perhaps the trial’s most enduring lesson is methodological. The editorial demonstrates that randomised, blinded evaluation of an established, guideline-recommended invasive procedure is accepted by patients, accepted by many expert physicians, and feasible across multiple centres and countries. Sham-controlled designs are particularly important when evaluating subjective or patient-reported outcomes, because such endpoints are vulnerable to placebo effects, expectations, regression to the mean and the effects of intensified clinical care. Just as placebo controls are indispensable for drug therapies, the incremental effect of an invasive or surgical procedure on how patients feel cannot be reliably determined without an appropriate sham control. PVI-SHAM-AF may thus be remembered less for what it says about ablation alone and more for how it resets the standard of evidence for procedural medicine.

Subject of Research: A sham-controlled randomised trial evaluating catheter ablation for symptom relief and rhythm control in patients with symptomatic atrial fibrillation.

Article Title: PVI-SHAM-AF: what does this trial tell us about catheter ablation and symptoms in patients with atrial fibrillation?

Article References: Laufs, U., Böhm, M., Mahfoud, F., & Wachter, R. (2026). PVI-SHAM-AF: what does this trial tell us about catheter ablation and symptoms in patients with atrial fibrillation?. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-026-03016-z

Image Credits: AI Generated

DOI: 10.1007/s00392-026-03016-z

Keywords: atrial fibrillation, catheter ablation, pulmonary vein isolation, sham-controlled trial, quality of life, AFEQT score, placebo effect, rhythm control, patient-reported outcomes, PVI-SHAM-AF, cardiology, clinical trial